Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 34, Issue 5, 2016, Pages 235.e11-235.e16

  Meyer, Christian P ^a   Pantel, Klaus ^a   Tennstedt, Pierre ^a   Stroelin, Petra ^a   Schlomm, Thorsten ^a   Heinzer, Hans ^a   Riethdorf, Sabine ^a   Steuber, Thomas ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Biochemical recurrence; Circulating tumor cells; Prostate cancer; Prostatectomy

Indexed keywords

BIOLOGICAL MARKER; CD45 ANTIGEN; CYTOKERATIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; BIOCHEMICAL RECURRENCE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CIRCULATING TUMOR CELL; EPITHELIUM CELL; GLEASON SCORE; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; AGED; ANALYSIS OF VARIANCE; BLOOD; KAPLAN MEIER METHOD; PATHOLOGY; PROCEDURES; PROGNOSIS; PROSTATIC NEOPLASMS; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; TUMOR EMBOLISM; TUMOR RECURRENCE;

AGED; ANALYSIS OF VARIANCE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PREOPERATIVE PERIOD; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84954306642     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2015.12.003     Document Type: Article

References (37)

1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014, 64:9-29.
2. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. J Am Med Assoc 1999, 281:1591-1597.
3. Kattan M.W., Eastham J.A., Stapleton A.M., Wheeler T.M., Scardino P.T. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998, 90:766-771.
4. Kattan M.W., Wheeler T.M., Scardino P.T. Post-operative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999, 17:1499-1507.
5. Steuber T., Vickers A.J., Haese A., Becker C., Pettersson K., Chun F.K., et al. Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum. Int J Cancer 2006, 118:1234-1240.
6. Shariat S.F., Walz J., Roehrborn C.G., Zlotta A.R., Perrotte P., Suardi N., et al. External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy. J Clin Oncol 2008, 26:1526-1531.
7. Cohen S.J., Punt C.J., Iannotti N., Saidman B.H., Sabbath K.D., Gabrail N.Y., et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:3213-3221.
8. Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Matera J., Miller M.C., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004, 351:781-791.
9. de Bono J.S., Scher H.I., Montgomery R.B., Parker C., Miller M.C., Tissing H., et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008, 14:6302-6309.
10. Hou J.M., Krebs M.G., Lancashire L., Sloane R., Backen A., Swain R.K., et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol 2012, 30:525-532.
11. Bidard F.C., Peeters D.J., Fehm T., Nole F., Gisbert-Criado R., Mavroudis D., et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol 2014, 15:406-414.
12. Goldkorn A., Ely B., Quinn D.I., Tangen C.M., Fink L.M., Xu T., et al. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 2014, 32:1136-1142.
13. Scher H.I., Heller G., Molina A., Attard G., Danila D.C., Jia X., et al. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J Clin Oncol 2015, 33:1348-1355.
14. Scher H.I., Jia X., de Bono J.S., Fleisher M., Pienta K.J., Raghavan D., et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 2009, 10:233-239.
15. Davis J.W., Nakanishi H., Kumar V.S., Bhadkamkar V.A., McCormack R., Fritsche H.A., et al. Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. J Urol 2008, 179:2187-2191. [discussion 91].
16. Helo P., Cronin A.M., Danila D.C., Wenske S., Gonzalez-Espinoza R., Anand A., et al. Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival. Clin Chem 2009, 55:765-773.
17. Khurana K.K., Grane R., Borden E.C., Klein E.A. Prevalence of circulating tumor cells in localized prostate cancer. Curr Urol 2013, 7:65-69.
18. Riethdorf S., Fritsche H., Muller V., Rau T., Schindlbeck C., Rack B., et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 2007, 13:920-928.
19. Kolostova K., Broul M., Schraml J., Cegan M., Matkowski R., Fiutowski M., et al. Circulating tumor cells in localized prostate cancer: isolation, cultivation in vitro and relationship to T-stage and Gleason score. Anticancer Res 2014, 34:3641-3646.
20. Pal S.K., He M., Wilson T., Liu X., Zhang K., Carmichael C., et al. Detection and phenotyping of circulating tumor cells in high-risk localized prostate cancer. Clin Genitourin Cancer 2015, 13:130-136.
21. Thalgott M., Rack B., Maurer T., Souvatzoglou M., Eiber M., Kreß V., et al. Detection of circulating tumor cells in different stages of prostate cancer. J Cancer Res Clin Oncol 2013, 139:755-763.
22. Loh J., Jovanovic L., Lehman M., Capp A., Pryor D., Harris M., et al. Circulating tumor cell detection in high-risk non-metastatic prostate cancer. J Cancer Res Clin Oncol 2014, 140:2157-2162.
23. Shao C., Liao C-P., Hu P., Chu C-Y., Zhang L., Bui M.H., et al. Detection of live circulating tumor cells by a class of near-infrared heptamethine carbocyanine dyes in patients with localized and metastatic prostate cancer. PLoS One 2014, 9:e88967.
24. Rack B., Schindlbeck C., Juckstock J., Andergassen U., Hepp P., Zwingers T., et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst 2014, 106. http://dx.doi.org/10.1093/jnci/dju066.
25. Chun F.K., Briganti A., Lebeau T., Fradet V., Steuber T., Walz J., et al. The 2002 AJCC pT2 substages confer no prognostic information on the rate of biochemical recurrence after radical prostatectomy. Eur Urol 2006, 49:273-278. [discussion 8-9].
26. Han M., Walsh P.C., Partin A.W., Rodriguez R. Ability of the 1992 and 1997 American Joint Committee on Cancer staging systems for prostate cancer to predict progression-free survival after radical prostatectomy for stage T2 disease. J Urol 2000, 164:89-92.
27. Cho Y.M., Jung S.J., Cho N., Kim M.J., Kattan M.W., Yu C., et al. Impact of international variation of prostate cancer on a predictive nomogram for biochemical recurrence in clinically localised prostate cancer. World J Urol 2014, 32:399-405.
28. Kang M., Jeong C.W., Choi W.S., Park Y.H., Cho S.Y., Lee S., et al. Pre- and post-operative nomograms to predict recurrence-free probability in korean men with clinically localized prostate cancer. PLoS One 2014, 9:e100053.
29. Suardi N., Porter C.R., Reuther A.M., Walz J., Kodama K., Gibbons R.P., et al. A nomogram predicting long-term biochemical recurrence after radical prostatectomy. Cancer 2008, 112:1254-1263.
30. Gasch C., Bauernhofer T., Pichler M., Langer-Freitag S., Reeh M., Seifert A.M., et al. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin Chem 2013, 59:252-260.
31. Van der Auwera I., Peeters D., Benoy I.H., Elst H.J., Van Laere S.J., Prove A., et al. Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer. Br J Cancer 2010, 102:276-284.
32. Alix-Panabieres C., Pantel K. Challenges in circulating tumour cell research. Nat Rev Cancer 2014, 14:623-631.
33. Antonarakis E.S., Lu C., Wang H., Luber B., Nakazawa M., Roeser J.C., et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014, 371:1028-1038.
34. Lohr J.G., Adalsteinsson V.A., Cibulskis K., Choudhury A.D., Rosenberg M., Cruz-Gordillo P., et al. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol 2014, 32:479-484.
35. Schwarzenbach H. Circulating nucleic acids and protease activities in blood of tumor patients. Expert Opin Biol Ther 2012, 12:S163-S169.
36. Bettegowda C., Sausen M., Leary R.J., Kinde I., Wang Y., Agrawal N., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014, 6:224ra24.
37. Heitzer E., Auer M., Ulz P., Geigl J.B., Speicher M.R. Circulating tumor cells and DNA as liquid biopsies. Genome Med 2013, 5:73.